OBJECTIVETo analysis and discuss the early diagnosis and treatment of fat embolism syndrome caused by the injuries in Wenchuan earthquake happened in May 12th, 2008.METHODSTo carry out dynamic blood and oxygen analysis and blood routine examination for the 13 fat embolism syndrome patients wounded in the earthquake, and combine with clinical features and early diagnosis, inject hydrocortisone injection, dextran 40 glucose injection and Dan Shen Root injection. Meanwhile, pay attention to supporting the respiratory function and correcting hypoxemia.RESULTSOf 13 patients, 12 cases were rescued successfully, and the successful rate was 92.3%, while one cases died from respirometric failure with fat embolism syndrome and secondary hemorrhagic pneumonia.CONCLUSIONSThe key to treating fat embolism syndrome is the early diagnosis and timely and accurate treatment. Supporting the respiratory function, correcting hypoxemia and early high-dose combination of hormone treatment are the effective treatment methods.

01 Mar 2002·Se pu = Chinese journal of chromatography

Endotoxin removal in some medicines and human serum albumin solution by affinity membranes.

Article

Author: Liu, Xue-Liang ; Li, Jing-Hua ; Wei, Gui-Lin ; Shang, Zhen-Hua ; Liu, Ying

Three kinds of affinity membranes utilized for endotoxin removal, namely, chitosan affinity membrane (KFCC517), hydrophobic and cationic charged membrane (KFCG316) and metal chelate affinity membrane (KFCM402) were prepared by using cellulose membrane as support. The adsorbability and applications of the membranes in endotoxin removal were investigated. The results showed that all of these affinity membranes could be utilized for endotoxin removal in several kinds of solutions. The factors affecting endotoxin removal such as ionic strength, pH value and flow rate were investigated, and the results were discussed. Three cartridges of membranes KFCC517, KFCG316 and KFCM402 were utilized for endotoxin removal in human serum albumin solution. The cartridge of membrane KFCC517 also was utilized in medicine injections, such as hydrocortisone, puerarin, tetracaine hydrochloride and dextran 40 glucose. Under the optimal conditions, the removal efficiencies of endotoxin were over 80% and the recoveries of desirable substances were over 95%.

100 Deals associated with Dextran/D-Glucopyranose

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Shock	Japan	Otsuka Pharmaceutical Factory, Inc.	19 May 1970
Thrombosis	Japan	Otsuka Pharmaceutical Factory, Inc.	19 May 1970

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2023	Not Applicable	-	-	Low molecular weight iron dextran (LMW ID)	(qyqkkhfnun) = dzwisizjjm mppgvfymjn (asvnlcjtmy ) View more	-	10 Dec 2023
				Low Molecular Weight Iron Dextran (Premedication)	(qyqkkhfnun) = lrudlnlevg mppgvfymjn (asvnlcjtmy )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Dextran/D-Glucopyranose

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation